Allogene Therapeutics
Ren Song is a Principal Scientist at Allogene Therapeutics since February 2021, having previously held the position of Senior Scientist at the same company. Prior to this role, Ren Song served as a Postdoctoral Researcher at Stanford University School of Medicine from July 2016 to January 2021, focusing on enhancing AAV viral vectors for gene therapy delivery across the human blood-brain barrier under the guidance of Professor Mark A. Kay. Ren Song earned a Doctor of Philosophy (PhD) in Molecular Biology from Princeton University, where studies were conducted from 2010 to 2016, and holds a Bachelor of Science (BS) in Life Science and Biotechnology from Wuhan University.
This person is not in the org chart
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.